Value through Innovation28 January 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


Boehringer Ingelheim Establishes Translational Research Collaboration with Harvard University in Areas of Unmet Medical Need


Boehringer Ingelheim announces changes to Board of Managing Directors: Joachim Hasenmaier to lead new Board Division Consumer Healthcare and Animal Health


New publication in The Lancet: Two-year study in over 1,500 patients compares Trajenta® (linagliptin) to the commonly prescribed sulphonylurea glimepiride

- EX US & UK Medical Media Only

No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa® (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery


First study to evaluate alternative to warfarin for mechanical heart valve patients launched with Pradaxa® (dabigatran etexilate)

- For Non-US, Non-UK & Non-Canadian Media Only

AF patients who require surgery benefit from a shorter treatment interruption on dabigatran etexilate (Pradaxa®) compared to warfarin

- For Non-US, Non-UK & Non-Canadian Media Only

Boehringer Ingelheim BioXcellence:
Distinctive brand for the biopharmaceutical contract manufacturing business


Boehringer Ingelheim once again certified as a family-friendly company


Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine

- EX UK. Medical Media Only.

New analysis presented at ADA shows improvement in albuminuria with linagliptin in patients at high risk of declining renal function

- EX US & UK. Medical Media Only.

New data demonstrate sustained glucose reduction and weight loss up to 90 weeks with investigational SGLT-2 inhibitor, empagliflozin*

- EX US & UK. Medical Media Only.

New linagliptin phase III data demonstrate significant reductions in blood glucose with no additional risk of hypoglycaemia when combined with insulin in patients with type 2 diabetes

- EX US & UK. Medical Media Only.

FDA affirms superiority of Pradaxa® (dabigatran etexilate) 150mg over warfarin in reduction of both ischaemic and haemorrhagic strokes

- For Non-US, Non-UK & Non-Canadian Media Only

Boehringer Ingelheim and Lilly to feature 30 presentations on type 1 and type 2 diabetes at the 72nd American Diabetes Association Scientific Sessions

- EX US & UK. Medical Media Only.

Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial

- For NON-US media only

Boehringer Ingelheim launches first-of-a-kind fundraising model to support disease awareness projects

- For NON-US Media Only

Boehringer Ingelheim expands development capacities with new technical centre


Boehringer Ingelheim further strengthens animal health presence in China: Manufacturing joint venture for veterinary vaccines